Trials / Completed
CompletedNCT06917872
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
An Open-label, Fixed-sequence, Two-period Phase I Trial to Evaluate the Effect of Multiple Oral Doses of Erythromycin, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of BI 1291583 at Steady State in Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1291583 | BI 1291583 |
| DRUG | erythromycin | erythromycin |
Timeline
- Start date
- 2025-04-29
- Primary completion
- 2025-09-09
- Completion
- 2025-09-09
- First posted
- 2025-04-09
- Last updated
- 2025-09-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06917872. Inclusion in this directory is not an endorsement.